• A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance

  • Sep 30 2024
  • Length: 33 mins
  • Podcast

A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance

Listen for free

View show details

  • Summary

  • In this episode, listen to Matthew S. Davids, MD, MMSc​, and Lindsey Roeker, MD, discuss BTK inhibitor resistance and how it shapes treatment choices for patients with CLL, including:

    • Contemporary treatment paradigms for patients with CLL
    • Safety and efficacy of current regimens
    • Molecular testing, including when and how to test for BTK inhibitor resistance
    • Considering BTK inhibitor resistance when sequencing therapy

    Program faculty:

    Matthew S. Davids, MD, MMSc​
    Associate Professor of Medicine​
    Harvard Medical School​
    Leader, Lymphoma Program​
    Dana-Farber/Harvard Cancer Center​
    Director of Clinical Research​
    Division of Lymphoma​
    Dana-Farber Cancer Institute​
    Boston, Massachusetts​​

    Lindsey Roeker, MD​
    Assistant Attending​
    CLL Program Director​
    Department of Medicine​
    Memorial Sloan Kettering Cancer Center​
    New York, New York

    Resources:
    To review a CME-certified text activity and download slides associated with this podcast discussion, please visit the program page.
    Show more Show less
Show more Show less

What listeners say about A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available